US · Healthcare · Biotechnology
EPS came in at -0.89 against a street estimate of -0.68 — a miss of 30.9%.
with an average price target of $24.12.
| Fund | Stake |
|---|---|
| EQT Fund Management S.à r.l. | 14.58% |
| RA Capital Management, LLC | 9.63% |
| Pivotal bioVenture Partners Investment Advisor LLC | 5.31% |
| RTW INVESTMENTS, LLC | 4.14% |
| JPMorgan Chase & Co | 4.02% |
| Nan Fung Group Holdings Ltd | 3.97% |
| Andera Partners | 3.84% |
| SymBiosis Capital Partners, LLC | 3.53% |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Evommune, Inc. — free to start.
Google PlayApp StoreData updated 2026-09-18.